Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDl-1 treatment

Oncotarget

Volumn 8, Issue 5, 2017, Pages 8890-8899

  Botticelli, Andrea ^b   Zizzari, Ilaria ^a   Mazzuca, Federica ^b   Ascierto, Paolo Antonio ^d   Putignani, Lorenza ^c   Marchetti, Luca ^a   Napoletano, Chiara ^a   Nuti, Marianna ^a   Marchetti, Paolo ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

CTLA 4; Immunotherapy; Microbiome; PD 1; PDL 1

Indexed keywords

ANTIBIOTIC AGENT; ATEZOLIZUMAB; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; DURVALUMAB; NIVOLUMAB; PEMBROLIZUMAB; PREBIOTIC AGENT; PROBIOTIC AGENT; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN;

CANCER IMMUNOTHERAPY; DIET; DRUG EFFICACY; DRUG RESPONSE; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INTESTINE FLORA; MELANOMA; NONHUMAN; REVIEW; TUMOR IMMUNITY; ANIMAL; DRUG EFFECT; GASTROINTESTINAL TRACT; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; NEOPLASM; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HOST-PATHOGEN INTERACTIONS; HUMANS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 85016945039     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12985     Document Type: Review

References (90)

1. McNutt M. Cancer immunotherapy. Science [Internet]. [cited 2016 Oct 24]; 342: 1417. doi: 10.1126/ science.1249481.
2. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3 -potential mechanisms of action. Nat Rev Immunol. 2014; 15: 45-56. doi: 10.1038/nri3790.
3. Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science [Internet]. 1995 [cited 2016 Oct 24]; 270: 932-3. Available from http://www.ncbi.nlm. nih.gov/pubmed/7481795.
4. Allison JP. Checkpoints. Cell [Internet]. 2015 [cited 2016 Oct 24]; 162: 1202-5. doi: 10.1016/j.cell.2015.08.047.
5. Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Letters. 2014. p. 368-76. doi: 10.1016/j.febslet.2013.10.015.
6. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen T-T, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015; 33: 1889-94. doi: 10.1200/JCO.2014.56.2736.
7. Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015; 15: 457-72. doi: 10.1038/nrc3973.
8. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. European Journal of Cancer. 2016. p. 139-48. doi: 10.1016/j. ejca.2015.11.016.
9. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013; 14: 1212-8. doi: 10.1038/ni.2762.
10. Lázár-Molnár E, Yan Q, Cao E, Ramagopal U, Nathenson SG, Almo SC. Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A. 2008; 105: 10483-8. doi: 10.1073/ pnas.0804453105.
11. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002; 169: 5538-45. doi: 10.4049/jimmunol.169.10.5538.
12. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006; 439: 682-7. doi: 10.1038/nature04444.
13. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8: 467-77. doi: 10.1038/nri2326.
14. Zang X, Allison JP. The B7 family and cancer therapy: Costimulation and coinhibition. Clinical Cancer Research. p. 5271-9. doi: 10.1158/1078-0432.CCR-07-1030.
15. John LB, Devaud C, Duong CPM, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013; 19: 5636-46. doi: 10.1158/1078-0432.CCR-13-0458.
16. Sui X, Ma J, Han W, Wang X, Fang Y, Li D, Pan H, Zhang L. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/ PD-L1 antibodies in cancer patients. Oncotarget. 2015; 6: 19393-404. doi: 10.18632/oncotarget.5107.
17. Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens RA, Laurie SA, Nathan FE, et al. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;. doi: 10.1200/ JCO.2016.66.9929.
18. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. The Lancet Oncology. 2016;. doi: 10.1016/S1470-2045(16)30098-5.
19. Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, et al. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol [Internet]. [cited 2016 Oct 24]; 34: 2969-79. doi: 10.1200/ JCO.2016.66.9861.
20. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;: 1803-13. doi: 10.1056/ NEJMoa1510665.
21. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373: 123-35. doi: 10.1056/NEJMoa1504627.
22. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373: 23-34. doi: 10.1056/NEJMoa1504030.
23. McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, Hodi FS, Kluger HM, Topalian SL, et al. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol. 2015; 33: 2013-20. doi: 10.1200/JCO.2014.58.1041.
24. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a nonrandomised, open-label, phase 2 trial. Lancet Oncol [Internet]. 2016 [cited 2016 Oct 24]; 17: 976-83. doi: 10.1016/S1470-2045(16)30053-5.
25. Armand P, Shipp MA, Ribrag V, Michot J-M, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2016 [cited 2016 Oct 24];: JCO673467. doi: 10.1200/ JCO.2016.67.3467.
26. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016; 17: 956-65. doi: 10.1016/S1470-2045(16)30066-3.
27. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016; 17: 717-26. doi: 10.1016/S1470-2045(16)00175-3.
28. Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau H-TT, Gubens MA, Hellmann MD, Dong D, Li C, et al. Systematic evaluation of pembrolizumab dosing in patients with advanced nonsmall-cell lung cancer. TL-27. Ann Oncol. 2016; 27 VN-r: 1291-8. doi: 10.1093/annonc/mdw174.
29. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu W-J, Weber JS, Gangadhar TC, Hersey P, Dronca R, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA [Internet]. 2016 [cited 2016 Oct 24]; 315: 1600-9. doi: 10.1001/jama.2016.4059.
30. Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. U.S. Food and Drug Administration Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. Oncologist. 2016;: 1-8. doi: 10.1634/theoncologist.2015-0498.
31. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, De Castro G, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced nonsmall-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 2016; 387: 1540-50. doi: 10.1016/ S0140-6736(15)01281-7.
32. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol. 2015; 16: 908-18. doi: 10.1016/S1470-2045(15)00083-2.
33. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn M, Felip E, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372: 2018-28. doi: 10.1056/NEJMoa1501824.
34. Robert C, Schachter J, Long G V., Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372: 2521-32. doi: 10.1056/NEJMoa1503093.
35. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387: 1837-46. doi: 10.1016/S0140-6736(16)00587-0.
36. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar A V, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;. doi: 10.1016/S0140-6736(16)00561-4.
37. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, ODonnell PH, Drakaki A, Tan W, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016; 34: 3119-25. doi: 10.1200/JCO.2016.67.9761.
38. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi NA. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A multicentre, phase 1b study. Lancet Oncol. 2016; 17: 299-308. doi: 10.1016/S1470-2045(15)00544-6.
39. Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Molecular Immunology. 2015. p. 4-17. doi: 10.1016/j. molimm.2015.02.009.
40. Karin M, Jobin C, Balkwill F. Chemotherapy, immunity and microbiota--a new triumvirate? Nat Med [Internet]. NIH Public Access; 2014 [cited 2016 Oct 24]; 20: 126-7. doi: 10.1038/nm.3473.
41. Burcelin R, Serino M, Chabo C, Garidou L, Pomié C, Courtney M, Amar J, Bouloumié A. Metagenome and metabolism: The tissue microbiota hypothesis. Diabetes, Obesity and Metabolism. 2013. p. 61-70. doi: 10.1111/ dom.12157.
42. Flannigan KL, Geem D, Harusato A, Denning TL. Intestinal Antigen-Presenting Cells: Key Regulators of Immune Homeostasis and Inflammation. Am J Pathol. 2015; 185: 1809-19. doi: 10.1016/j.ajpath.2015.02.024.
43. Mai V. Dietary modification of the intestinal microbiota. Nutr Rev. 2004; 62: 235-42. doi: 10.1111/j.1753-4887.2004.tb00045.x.
44. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology [Internet]. 2009 [cited 2016 Oct 24]; 136: 65-80. doi: 10.1053/j.gastro.2008.10.080.
45. Tlaskalová-Hogenová H, Štepánková R, Hudcovic T, Tucková L, Cukrowska B, Lodinová-Žádníková R, Kozáková H, Rossmann P, Bártová J, Sokol D, Funda DP, Borovská D, Reháková Z, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunology Letters. 2004. p. 97-108. doi: 10.1016/j.imlet.2004.02.005.
46. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, Gordon JI, Chervonsky A V. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008; 455: 1109-13. doi: 10.1038/nature07336.
47. Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, Wu C, Kleinewietfeld M, Kunder S, Hafler DA, Sobel RA, Regev A, Kuchroo VK. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol. 2012; 13: 991-9. doi: 10.1038/ni.2416; 10.1038/ni.2416.
48. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013; 500: 541-6. doi: 10.1038/nature12506.
49. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012; 22: 292-8. doi: 10.1101/gr.126573.111.
50. Rowland IR. The role of the gastrointestinal microbiota in colorectal cancer. Curr Pharm Des. 2009; 15: 1524-7. doi: 10.2174/138161209788168191.
51. Zhu Q, Gao R, Wu W, Qin H. The role of gut microbiota in the pathogenesis of colorectal cancer. Tumor Biology. p. 1285-300. doi: 10.1007/s13277-013-0684-4.
52. Chen H-M, Yu Y-N, Wang J-L, Lin Y-W, Kong X, Yang C-Q, Yang L, Liu Z-J, Yuan Y-Z, Liu F, Wu J-X, Zhong L, Fang D-C, et al. Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am J Clin Nutr. 2013; 97: 1044-52. doi: 10.3945/ajcn.112.046607.
53. Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S, Zhao L. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012; 6: 320-9. doi: 10.1038/ismej.2011.109.
54. Gold JS, Bayar S, Salem RR. Association of Streptococcus bovis bacteremia with colonic neoplasia and extracolonic malignancy: Commentary. Diseases of the Colon and Rectum. 2005. p. 180. doi: 10.1007/s10350-004-0732-7.
55. Peek Jr. RM, Blaser MJ, Peek RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002; 2: 28-37. doi: 10.1038/nrc703.
56. Yang Y, Wang X, Huycke T, Moore DR, Lightfoot S a, Huycke MM. Colon Macrophages Polarized by Commensal Bacteria Cause Colitis and Cancer through the Bystander Effect. Transl Oncol. 2013; 6: 596-606. doi: 10.1593/ tlo.13412.
57. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA, Holt RA. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012; 22: 299-306. doi: 10.1101/gr.126516.111.
58. McIntosh GH, Royle PJ, Playne MJ. A probiotic strain of L. acidophilus reduces DMH-induced large intestinal tumors in male Sprague-Dawley rats. Nutr Cancer. 1999; 35: 153-9. doi: 10.1207/S15327914NC352_9.
59. Sonnenberg GF, Artis D. Innate Lymphoid Cell Interactions with Microbiota: Implications for Intestinal Health and Disease. Immunity. 2012. p. 601-10. doi: 10.1016/j. immuni.2012.10.003.
60. Wu S, Shin J, Zhang G, Cohen M, Franco A, Sears CL. The Bacteroides fragilis toxin binds to a specific intestinal epithelial cell receptor. Infect Immun. 2006; 74: 5382-90. doi: 10.1128/IAI.00060-06.
61. Wu S, Rhee K-J, Albesiano E, Rabizadeh S, Wu X, Yen H-R, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CL. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med [Internet]. NIH Public Access; 2009 [cited 2016 Oct 24]; 15: 1016-22. doi: 10.1038/nm.2015.
62. Kwa M, Plottel CS, Blaser MJ, Adams S. The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer. J Natl Cancer Inst. 2016; 108: djw029. doi: 10.1093/jnci/djw029.
63. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, et al. The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide. Science (80-). 2013; 342: 971-6. doi: 10.1126/science.1240537.
64. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten R a, Molina D a, Salcedo R, Back T, Cramer S, Dai R-M, Kiu H, Cardone M, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013; 342: 967-70. doi: 10.1126/science.1240527.
65. Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CPM, Poirier-Colame V, Roux A, Becharef S, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science (80-). 2015; 350: 1079-84. doi: 10.1126/science.aad1329.
66. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, Pamer EG, Wolchok JD. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016; 7: 10391. doi: 10.1038/ ncomms10391.
67. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, Gabriele L, Proietti E, Bracci L. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res [Internet]. 2011 [cited 2016 Oct 24]; 71: 768-78. doi: 10.1158/0008-5472.CAN-10-2788.
68. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004; 34: 336-44. doi: 10.1002/ eji.200324181.
69. Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, Soria JC, Marty V, Vielh P, Robert C, Chaput N, Zitvogel L. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 2011; 71: 661-5. doi: 10.1158/0008-5472.CAN-10-1259.
70. Yang J, Liu K, Qu J, Wang X. The changes induced by cyclophosphamide in intestinal barrier and microflora in mice. Eur J Pharmacol [Internet]. 2013 [cited 2016 Oct 24]; 714: 120-4. doi: 10.1016/j.ejphar.2013.06.006.
71. Zwielehner J, Lassl C, Hippe B, Pointner A, Switzeny OJ, Remely M, Kitzweger E, Ruckser R, Haslberger AG. Changes in Human Fecal Microbiota Due to Chemotherapy Analyzed by TaqMan-PCR, 454 Sequencing and PCRDGGE Fingerprinting. Heimesaat MM, editor. PLoS One [Internet]. Public Library of Science; 2011 [cited 2016 Oct 24]; 6: e28654. doi: 10.1371/journal.pone.0028654.
72. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007; 13: 1050-9. doi: 10.1038/nm1622.
73. Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devinney R, Lynch T, Allen-Vercoe E. Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011; 17: 1971-8. doi: 10.1002/ibd.21606.
74. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host and Microbe. 2014. p. 317-28. doi: 10.1016/j.chom.2014.02.007.
75. Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: Inflammatory bowel disease and colitisassociated colon cancer. Frontiers in Immunology. 2012. doi: 10.3389/fimmu.2012.00107.
76. Imray CH, Radley S, Davis a, Barker G, Hendrickse CW, Donovan I a, Lawson a M, Baker PR, Neoptolemos JP. Faecal unconjugated bile acids in patients with colorectal cancer or polyps. Gut. 1992; 33: 1239-45. doi: 10.1136/ gut.33.9.1239.
77. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007; 7: 41-51. doi: 10.1038/nri1995.
78. Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology. 2004; 127: 80-93. doi: 10.1053/j.gastro.2004.03.054.
79. Bonfrate L, Tack J, Grattagliano I, Cuomo R, Portincasa P. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. Scand J Gastroenterol. 2013; 48: 995-1009. doi: 10.3109/00365521.2013.799220.
80. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009; 9: 313-24. doi: 10.1038/nri2515.
81. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Man Lei Y, Jabri B, Alegre M-L, Chang EB, Gajewski TF. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science (80-). 2015; 350: 1084-9. doi: 10.1126/science.aac4255.
82. Rabe H, Nordström I, Andersson K, Lundell AC, Rudin A. Staphylococcus aureus convert neonatal conventional CD4+ T cells into FOXP3+ CD25+ CD127low T cells via the PD-1/PD-L1 axis. Immunology. 2014; 141: 467-81. doi: 10.1111/imm.12209.
83. Maruya M, Kawamoto S, Kato LM, Fagarasan S. Impaired selection of IgA and intestinal dysbiosis associated with PD-1-deficiency. Gut Microbes [Internet]. Taylor & Francis; 2013 [cited 2016 Oct 24]; 4: 165-71. doi: 10.4161/ gmic.23595.
84. Kawamoto S, Tran TH, Maruya M, Suzuki K, Doi Y, Tsutsui Y, Kato LM, Fagarasan S. The Inhibitory Receptor PD-1 Regulates IgA Selection and Bacterial Composition in the Gut. Science (80-). 2012; 336: 485-9. doi: 10.1126/ science.1217718.
85. Rescigno M. A "fit" microbiota to potentiate cancer immunotherapy. Genome Med. 2015; 7: 1-2. doi: 10.1186/ s13073-015-0256-x.
86. Zagato E, Mazzini E, Rescigno M. The variegated aspects of Immunoglobulin A. Immunol Lett [Internet]. 2016 [cited 2016 Oct 24]; 178: 45-9. doi: 10.1016/j.imlet.2016.04.009.
87. Rescigno M. Tfr cells and IgA join forces to diversify the microbiota. Immunity.2014 Jul 17;41(1):9-11. doi: 10.1016/j.immuni.2014.06.012.
88. FransenF, Zagato E, Mazzini E, Fosso B, Manzari C, El Aidy S, Chiavelli A, D'Erchia AM, Sethi MK, PabstO, Marzano M, Moretti S, Romani L et al. BALB/c and C57BL/6 mice differ in generation of antigen-specific IgA and microbiota diversity.Immunity 2015:43:527-40. doi: 10.1016/j.immuni.2015.08.011.
89. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, Knight R. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107:11971-5. doi:10.1073/pnas.1002601107
90. Peterson DA, McNulty NP, Guruge JL, Gordon JI. IgA response to symbiotic bacteria as a mediator of gut homeostasis. Cell Host Microbe. 2007 Nov 15;2(5):328 39.10.1016/j.chom.2007.09.013